Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
about
Cyclooxygenase-1 orchestrates germinal center formation and antibody class-switch via regulation of IL-17Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints.An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?
P2860
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@ast
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@en
type
label
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@ast
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@en
prefLabel
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@ast
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@en
P2093
P2860
P1476
Characterizing new users of NSAIDs before and after rofecoxib withdrawal.
@en
P2093
Cara Usher
John Feely
Kathleen Bennett
Mary Teeling
P2860
P304
P356
10.1111/J.1365-2125.2006.02784.X
P407
P577
2006-10-19T00:00:00Z